Pregnancy outcome after treatment with the ergot derivative, cabergoline.
The goal of this article is to assess the reproductive safety of cabergoline, a new ergot derivative proposed in hyperprolactinemic disorders. Investigated in different animal species, the drug showed no teratogenic or embryotoxic effects on rabbits. Considering the dose envisaged for humans, large safety margins exist. Our sample consists of 226 pregnancies occuring in 205 women. Follow-up is available for 204. There were 24 miscarriages and three abortions induced because of major malformations (one Down syndrome in a 42-year-old woman, one limb-body wall complex, one hydrocephalus). Two of the 148 single liveborn infants had significant malformations: one megaureter, one scaphocephaly. This series shows no increase in miscarriage rate, a distribution of birthweights and sex ratio within the expected range, and no increased rate of congenital malformations. Follow-up of babies, limited to 107 cases, thus far indicates normal physical and mental development.
Robert
E
E
Institut Européen des Génomutations, Lyon, France.
Musatti
L
L
Piscitelli
G
G
Ferrari
C I
CI
D000014:Abnormalities, Drug-Induced / Q000209:etiology*; D000328:Adult; D001724:Birth Weight; D000077465:Cabergoline; D018491:Dopamine Agonists / Q000009:adverse effects* / Q000627:therapeutic use; D004873:Ergolines / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy; D007558:Italy; D011247:Pregnancy; D011256:Pregnancy Outcome
D018491:Dopamine Agonists; D004873:Ergolines; D000077465:Cabergoline